|
|||||
|
|
| 预防和治疗1型糖尿病的单克隆抗体teplizumab概述 | |
| 引用本文： | 马海燕 林海荣. 预防和治疗1型糖尿病的单克隆抗体teplizumab概述[J]. 中国药师, 2020, 0(6): 1166-1168 |
| 作者姓名： | 马海燕 林海荣 |
| 作者单位： | 临朐县人民医院药剂科 |
| 摘 要： | teplizumab是以CD3为靶抗原的重组人源化的单克隆抗体,能预防和治疗1型糖尿病。临床Ⅱ期和Ⅲ期试验已经证实了其有效性和安全性,展示了良好的临床应用前景。本文旨在介绍该药的药效学、药动学、临床疗效和安全性等信息,供临床参考。 |
| 关 键 词： | Teplizumab 单克隆抗体 1型糖尿病 CD3 |
Monoclonal Antibody Teplizumab for the Prevention and Treatment of Type 1 Diabetes |
|
| Ma Haiyan,Lin Hairong. Monoclonal Antibody Teplizumab for the Prevention and Treatment of Type 1 Diabetes[J]. China Pharmacist, 2020, 0(6): 1166-1168 | |
| Authors: | Ma Haiyan Lin Hairong |
| Affiliation: | (Department of Pharmacy,People's Hospital of Linqu,Shandong Linqu 262600,China) |
| Abstract: | Teplizumab is a humanized anti-CD3 human monoclonal antibody with promising activity in the prevention and treatment of patients with type 1 diabetes mellitus.The results from phase 2 and 3 trials further determined its safety and efficacy,showing a good prospect for clinical application.The article was intended to introduce its information about pharmacodynamics,pharmacokinetics,clinical efficacy and safety. |
| Keywords: | Teplizumab Monoclonal antibody Type 1 diabetes mellitus CD3 |
| 本文献已被 维普 等数据库收录！ | |
| 点击此处可从《中国药师》浏览原始摘要信息 | |
| 点击此处可从《中国药师》下载免费的PDF全文 | |